Eli Lilly and Company $LLY Holdings Lessened by Harbour Investments Inc.

Harbour Investments Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 8.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,232 shares of the company’s stock after selling 2,451 shares during the period. Harbour Investments Inc.’s holdings in Eli Lilly and Company were worth $29,196,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Pensioenfonds Rail & OV purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $7,713,000. IFG Advisory LLC grew its holdings in Eli Lilly and Company by 4.4% during the third quarter. IFG Advisory LLC now owns 4,522 shares of the company’s stock worth $5,232,000 after buying an additional 189 shares in the last quarter. Trillium Asset Management LLC raised its position in Eli Lilly and Company by 1,302.8% in the 3rd quarter. Trillium Asset Management LLC now owns 5,036 shares of the company’s stock valued at $5,831,000 after buying an additional 4,677 shares during the last quarter. Phoenix Financial Ltd. raised its position in Eli Lilly and Company by 0.3% in the 3rd quarter. Phoenix Financial Ltd. now owns 97,306 shares of the company’s stock valued at $105,333,000 after buying an additional 287 shares during the last quarter. Finally, Hansen & Associates Financial Group Inc. raised its position in Eli Lilly and Company by 16.8% in the 3rd quarter. Hansen & Associates Financial Group Inc. now owns 1,104 shares of the company’s stock valued at $1,292,000 after buying an additional 159 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $16.77 during midday trading on Friday, reaching $1,444.05. The company had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The company’s 50 day moving average price is $1,242.25 and its 200 day moving average price is $1,110.30. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.36 trillion, a P/E ratio of 46.87, a P/E/G ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,460.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $7.02 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Eli Lilly and Company News Summary

These are some of the LLY news items that stood out recently:

• Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
• Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study
• Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Truist Financial restated a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Finally, Royal Bank Of Canada upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.